Neoantigens in pediatric ALL could lead to cell-based therapies

Why a St. Jude's team thinks pediatric leukemia could be treated with neoantigen-targeted cell therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia.

The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations in tumors -- as tumor-specific targets for personalized cell-based immunotherapies (see "Neo Wave").

It had been thought

Read the full 500 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE